Pharming Group NV (PHAR) Stock Forecast & Price Target
Pharming Group NV · NASDAQ
$11.77+0.31 (+2.71%)
15-min delayed · Aug 25, 3:30 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Pharming Group NV, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $37.00 to $41.00, so the covering firms are broadly aligned. The average target of $38.67 sits 229% above the current $11.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.27 next quarter toward $0.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Pharming Group NV.
As of Aug, 3 of 3 firms rate PHAR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PHAR EPS & revenue forecast
EPS · NEXT QUARTER
$0.27
Range $0.27 – $0.27 · 1 analysts · +286% YoY
Next period, 1 analysts expect Pharming Group NV to earn $0.27 a share (range $0.27 – $0.27), versus $0.07 a year earlier. Full-year consensus is $0.46, growing to $0.31 the year after.
REVENUE · NEXT QUARTER
$115.5M
Range $109.6M – $123.6M · 1 analysts · +8% YoY
Revenue is expected to reach $115.5M (range $109.6M – $123.6M), +8.4% year-over-year. Full-year consensus is $382.8M, rising to $424.9M next year.
Top analysts covering Pharming Group NV
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PHAR.
#1
Jeff Jones
Oppenheimer · Rank #231
Buy
$40.00+239.8% to target
Overall win rate
33%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #298
Buy
$37.00+214.4% to target
Overall win rate
33%
+ Follow
#3
WI
Whitney Ijem
Canaccord Genuity · Rank #341
Buy
$38.00+222.9% to target
Overall win rate
32%
+ Follow
#4
MC
Michael Carrier
Oppenheimer
Buy
$39.00+231.4% to target
Coverage
—
+ Follow
#5
LC
Lucy Codrington
Jefferies
Buy
$14.00+18.9% to target
Coverage
—
+ Follow
PHAR stock forecast FAQ
What is PHAR's average 12-month price target?+
The 3 analysts with a live target average $38.67 for Pharming Group NV over the next 12 months, ranging from a $41.00 high to a $37.00 low.
Is PHAR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PHAR?+
The Street-high target is $41.00 (Oppenheimer), and the Street-low is $37.00 (HC Wainwright & Co.). The average of all 3 active targets is $38.67.
How many Wall Street analysts cover PHAR?+
3 analysts have an active rating on Pharming Group NV, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PHAR?+
Among analysts who currently cover PHAR, Jeff Jones of Oppenheimer has the strongest overall Quantellect track record (Rank #231). Their current call is Buy with a $40.00 target.
What is Pharming Group NV's projected EPS for next quarter?+
The consensus estimate is $0.27 per share (range $0.27 – $0.27) across 1 analysts. Full-year EPS is projected at $0.46, rising to $0.31 the following year.
How much revenue is Pharming Group NV expected to report next quarter?+
Consensus revenue is $115.5M (range $109.6M – $123.6M). Full-year revenue is projected at $382.8M, growing to $424.9M next year.
Have analysts been upgrading or downgrading PHAR lately?+
As of Aug, 3 of 3 firms rate PHAR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PHAR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
